NasdaqGS - Delayed Quote USD

FibroGen, Inc. (FGEN)

0.3442
+0.0306
+(9.76%)
At close: 4:00:01 PM EDT
0.3401
-0.00
(-1.19%)
After hours: 7:05:44 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
6,996
29,621
46,803
140,734
235,309
Cost of Revenue
-5,530
15,561
3,962
20,280
12,871
Gross Profit
12,526
14,060
42,841
120,454
222,438
Operating Expense
109,100
145,022
352,956
421,479
510,968
Operating Income
-96,574
-130,962
-310,115
-301,025
-288,530
Net Non Operating Interest Income Expense
-4,938
-2,951
-501
6,156
-2,153
Other Income Expense
--
-19,454
-12,606
--
--
Pretax Income
-121,092
-153,367
-323,222
-294,869
-290,683
Tax Provision
-274
-269
-252
358
347
Earnings from Equity Interest Net of Tax
--
--
2,638
1,573
1,007
Net Income Common Stockholders
-10,007
-47,579
-284,232
-293,654
-290,023
Diluted NI Available to Com Stockholders
-10,007
-47,579
-284,232
-293,654
-290,023
Basic EPS
-0.10
-0.48
-2.92
-3.14
-3.14
Diluted EPS
-0.10
-0.48
-2.92
-3.14
-3.14
Basic Average Shares
100,537
100,044
97,303
93,582
92,349
Diluted Average Shares
100,537
100,044
97,303
93,582
92,349
Total Operating Income as Reported
-116,154
-150,416
-322,721
-301,025
-288,530
Total Expenses
103,570
160,583
356,918
441,759
523,839
Net Income from Continuing & Discontinued Operation
-10,007
-47,579
-284,232
-293,654
-290,023
Normalized Income
-101,282.3045
-133,682.9080
-310,376.6060
-293,654
-290,023
Interest Income
3,474
5,296
7,594
7,596
--
Interest Expense
8,412
8,247
8,095
1,440
2,153
Net Interest Income
-4,938
-2,951
-501
6,156
-2,153
EBIT
-112,680
-145,120
-315,127
-293,429
-288,530
EBITDA
-110,481
-142,428
-305,197
-282,825
-273,721
Reconciled Cost of Revenue
-5,530
15,561
3,962
20,280
12,871
Reconciled Depreciation
2,199
2,692
9,930
10,604
14,809
Net Income from Continuing Operation Net Minority Interest
-120,818
-153,098
-322,970
-293,654
-290,023
Total Unusual Items Excluding Goodwill
-19,580
-19,454
-12,606
0
0
Total Unusual Items
-19,580
-19,454
-12,606
0
0
Normalized EBITDA
-90,901
-122,974
-292,591
-282,825
-273,721
Tax Rate for Calcs
0
0
0
0.0002
0.0003
Tax Effect of Unusual Items
-44.3045
-38.9080
-12.6060
0
0
12/31/2021 - 11/14/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

KPTI Karyopharm Therapeutics Inc.
5.16
+0.59%
 
NKTR Nektar Therapeutics
0.6871
-1.14%
 
MGNX MacroGenics, Inc.
1.5700
-1.26%
 
ALXO ALX Oncology Holdings Inc.
0.4288
-0.58%
 
MRSN Mersana Therapeutics, Inc.
0.3900
+1.30%
 
STRO Sutro Biopharma, Inc.
0.8997
+2.44%
 
ATRA Atara Biotherapeutics, Inc.
7.00
+4.01%
 
CHRS Coherus BioSciences, Inc.
0.8161
+2.01%
 
MBRX Moleculin Biotech, Inc.
0.9799
-1.37%
 
HRTX Heron Therapeutics, Inc.
1.9200
0.00%